Study Identifies Optimal LSD Dose for Sustained Anxiety Relief
AI-Generated Summary
A phase 2b clinical trial found that a 100 microgram dose of MM120, a pharmaceutical LSD tablet, significantly reduced symptoms of generalised anxiety disorder (GAD) for up to 12 weeks. The study, published in JAMA, involved nearly 200 patients and demonstrated a marked improvement in anxiety scores compared to placebo. Researchers believe these findings could be transformative for GAD treatment, with developer MindMed now advancing to phase three trials.
In a nutshell
This research offers a potentially paradigm-shifting approach to treating generalised anxiety disorder, moving beyond traditional therapies and SSRIs. The prospect of a single dose providing long-term relief could revolutionize patient care and represents a significant step forward for psychedelic-assisted therapy in mainstream psychiatry.
Source: Belfast Telegraph
